Stock Events

Stock Events

Black Diamond Therapeutics 

$2.35
97
+$0.22+10.33% Thursday 03:01

Statistics

Day High
2.36
Day Low
2.33
52W High
-
52W Low
-
Volume
164
Avg. Volume
-
Mkt Cap
133.89M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.27
-0.23
-0.19
-0.15
Expected EPS
-0.185
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-139.35MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 14.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BDTX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of cancer treatment research, which puts it in direct competition with Black Diamond's approach to targeting mutations.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad oncology portfolio, including targeted therapies that compete with Black Diamond's precision oncology products.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a strong presence in the cancer treatment market, including targeted therapies and immunooncology, competing with Black Diamond's cancer focus.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a diverse oncology portfolio, including precision medicine and targeted therapies, making it a competitor in the same space as Black Diamond.
Merck
MRK
Mkt Cap214.76B
Merck is known for its cancer treatments, including targeted therapy and immunotherapy options, competing with Black Diamond's targeted cancer therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has expanded its oncology portfolio, including cell therapies and targeted treatments, positioning it as a competitor to Black Diamond.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad range of cancer treatments, including targeted therapies that compete with Black Diamond's approach to precision oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals focuses on developing drugs for cancer, among other diseases, with a strategy that includes precision medicine, competing with Black Diamond.

About

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
ISIN
US09203E1055

Listings

XNAS
US
BDTX
BOATS
BOATS
BDTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Black Diamond Therapeutics stock price today?▼
The current price of BDTX.BOATS is $2.35 USD — it has increased by +10.33% in the past 24 hours. Watch Black Diamond Therapeutics stock price performance more closely on the chart.
What is Black Diamond Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Black Diamond Therapeutics stocks are traded under the ticker BDTX.BOATS.
What is Black Diamond Therapeutics market cap?▼
Today Black Diamond Therapeutics has the market capitalization of 133.89M
When is the next Black Diamond Therapeutics earnings date?▼
Black Diamond Therapeutics is going to release the next earnings report on May 13, 2026.
What were Black Diamond Therapeutics earnings last quarter?▼
BDTX.BOATS earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.18 USD resulting in a -50.93% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Black Diamond Therapeutics revenue for the last year?▼
Black Diamond Therapeutics revenue for the last year amounts to 0 USD.
What is Black Diamond Therapeutics net income for the last year?▼
BDTX.BOATS net income for the last year is -139.35M USD.
When did Black Diamond Therapeutics complete a stock split?▼
Black Diamond Therapeutics has not had any recent stock splits.